Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 11/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 8/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.42 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.42 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22957032 | 1.00 | SLC7A5 (0.58) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL4420457 | 1.00 | SLC7A5 (0.58) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL4421189 | 1.00 | SLC7A5 (0.58) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL4421181 | 1.00 | SLC7A5 (0.58) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL188082 | 1.00 | SLC7A5 (0.58) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL23391696 | 1.00 | SLC7A5 (0.58) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL188081 | 1.00 | SLC7A5 (0.58) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL20641484 | 1.00 | SLC7A5 (0.58) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| Hydrochloric Acid SCHEMBL23391711 | 0.98 | SLC7A5 (0.56) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| Hydrochloric Acid SCHEMBL23391697 | 0.98 | SLC7A5 (0.56) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034084-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARM INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12427130-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12378263-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3615019-B1 | MODULATOR OF SESTRIN-GATOR2 INTERACTION FOR USE IN THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION | NAVITOR PHARM INC (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4556069-A2 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20240091184-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2024-03-21 | — | — | US | disclosed |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| EP-4112611-A2 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| US-20090326196-A1 | Proteins Containing a Fluorinated Amino Acid, and Methods of Using Same | TRUSTEES OF TUFTS COLLEGE | 2009-12-31 | — | — | US | disclosed |
| US-7371867-B2 | Non-racemic trifluoroleucine, and methods of making and using | TRUSTEES OF TUFTS COLLEGE (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371867-B2 | Non-racemic trifluoroleucine, and methods of making and using | TRUSTEES OF TUFTS COLLEGE (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371867-B2 | Non-racemic trifluoroleucine, and methods of making and using | TRUSTEES OF TUFTS COLLEGE (US) | 2008-05-13 | — | — | US | disclosed |
| US-20070112200-A1 | Non-racemic hexafluoreleucine,and methods of making and using it | TRUSTEES OF TUFTS COLLEGE (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070112200-A1 | Non-racemic hexafluoreleucine,and methods of making and using it | TRUSTEES OF TUFTS COLLEGE (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070112200-A1 | Non-racemic hexafluoreleucine,and methods of making and using it | TRUSTEES OF TUFTS COLLEGE (US) | 2007-05-17 | — | — | US | disclosed |
| US-7132559-B2 | Non-racemic hexafluoroleucine, and methods of making and using it | TRUSTEES OF TUFTS COLLEGE (US) | 2006-11-07 | — | — | US | disclosed |
| US-20040138493-A1 | Non-racemic hexafluoreleucine, and methods of making and using it | TRUSTEES OF TUFTS COLLEGE | 2004-07-15 | — | — | US | disclosed |
| WO-2002068592-A2 | NON-RACEMIC HEXAFLUORELEUCINE, AND METHODS OF MAKING AND USING IT | TRUSTEES OF TUFTS COLLEGE (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034084-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | RICTOR, RPTOR, MTOR | SLC7A5 374/4885SLC1A2 26/4885SLC1A1 75/4885 |
| US-20240091184-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | SLC7A5 2349/4885SLC1A2 138/4885SLC1A1 289/4885 |
| US-20090326196-A1 | Proteins Containing a Fluorinated Amino Acid, and Methods of Using Same | DNPEP, NPEPPS, ANPEP | SLC7A5 618/4885SLC1A2 647/4885SLC1A1 473/4885 |
| US-12378263-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | SLC7A5 2349/4885SLC1A2 138/4885SLC1A1 289/4885 |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | SLC7A5 2349/4885SLC1A2 138/4885SLC1A1 289/4885 |
| US-12427130-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | SLC7A5 2349/4885SLC1A2 138/4885SLC1A1 289/4885 |
| US-20070112200-A1 | Non-racemic hexafluoreleucine,and methods of making and using it | CRYZ, FABP5, FAU | SLC7A5 1167/4885SLC1A2 2705/4885SLC1A1 2290/4885 |
| US-20040138493-A1 | Non-racemic hexafluoreleucine, and methods of making and using it | NPFFR1, FNTB, CRYZ | SLC7A5 1102/4885SLC1A2 1904/4885SLC1A1 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.